What is Oncternal Therapeutics Price-to-Tangible-Book?
As of today (2024-04-25), Oncternal Therapeutics's share price is $8.545. Oncternal Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $10.19. Hence, Oncternal Therapeutics's Price to Tangible Book Ratio of today is 0.84.
The historical rank and industry rank for Oncternal Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
ONCT'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.72 Med: 3.19 Max: 57.06
Current: 0.84
During the past 13 years, Oncternal Therapeutics's highest Price to Tangible Book Ratio was 57.06. The lowest was 0.72. And the median was 3.19.
ONCT's Price-to-Tangible-Book is ranked better than 86.15% of 1220
companies
in the Biotechnology industry
Industry Median: 2.67
vs ONCT: 0.84
A closely related ratio is called PB Ratio. As of today, Oncternal Therapeutics's share price is $8.545. Oncternal Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $10.19. Hence, Oncternal Therapeutics's P/B Ratio of today is 0.84.
Oncternal Therapeutics Price-to-Tangible-Book Historical Data
The historical data trend for Oncternal Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Oncternal Therapeutics's Price-to-Tangible-Book
For the Biotechnology subindustry, Oncternal Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncternal Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Oncternal Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Oncternal Therapeutics Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Oncternal Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Oncternal Therapeutics (Oncternal Therapeutics) Business Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ONCT has been successfully added to your 